Hutchmed (China) Limited Total Voting Rights (0246O)

TIDMHCM

RNS Number : 0246O

Hutchmed (China) Limited

29 September 2023

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ -- Friday, September 29, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 29, 2023, the issued share capital of HUTCHMED consisted of 871,035,940 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 871,035,940 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 871,035,940 ordinary shares would be equivalent to 871,035,940 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,207,188 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

Contacts

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 306 4490 
 
Media Enquiries 
  Ben Atwell / Alex Shaw,                                    +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
   FTI Consulting                                            545 055 (Mobile) / HUTCHMED@fticonsulting.com 
  Zhou Yi, Brunswick                                         +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure 
   Gordon                                                    +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRFZGZLGRRGFZM

(END) Dow Jones Newswires

September 29, 2023 04:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Nov 2024 to Dec 2024